These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
361 related articles for article (PubMed ID: 28481866)
1. Critical role of Myc activation in mouse hepatocarcinogenesis induced by the activation of AKT and RAS pathways. Xin B; Yamamoto M; Fujii K; Ooshio T; Chen X; Okada Y; Watanabe K; Miyokawa N; Furukawa H; Nishikawa Y Oncogene; 2017 Sep; 36(36):5087-5097. PubMed ID: 28481866 [TBL] [Abstract][Full Text] [Related]
2. Minimal cooperation between mutant Hras and c-myc or TGFα in the regulation of mouse hepatocyte growth or transformation in vivo. Stein TJ; Bowden M; Sandgren EP Liver Int; 2011 Oct; 31(9):1298-305. PubMed ID: 22093452 [TBL] [Abstract][Full Text] [Related]
3. Generation of combined hepatocellular-cholangiocarcinoma through transdifferentiation and dedifferentiation in p53-knockout mice. Liu Y; Xin B; Yamamoto M; Goto M; Ooshio T; Kamikokura Y; Tanaka H; Meng L; Okada Y; Mizukami Y; Nishikawa Y Cancer Sci; 2021 Aug; 112(8):3111-3124. PubMed ID: 34051011 [TBL] [Abstract][Full Text] [Related]
4. SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice. Delogu S; Wang C; Cigliano A; Utpatel K; Sini M; Longerich T; Waldburger N; Breuhahn K; Jiang L; Ribback S; Dombrowski F; Evert M; Chen X; Calvisi DF Oncotarget; 2015 Feb; 6(4):2222-34. PubMed ID: 25537506 [TBL] [Abstract][Full Text] [Related]
5. Activation of SRY accounts for male-specific hepatocarcinogenesis: Implication in gender disparity of hepatocellular carcinoma. Liu C; Ren YF; Dong J; Ke MY; Ma F; Monga SPS; Wu R; Lv Y; Zhang XF Cancer Lett; 2017 Dec; 410():20-31. PubMed ID: 28942012 [TBL] [Abstract][Full Text] [Related]
6. Transforming Growth Factor-β Promotes Liver Tumorigenesis in Mice via Up-regulation of Snail. Moon H; Ju HL; Chung SI; Cho KJ; Eun JW; Nam SW; Han KH; Calvisi DF; Ro SW Gastroenterology; 2017 Nov; 153(5):1378-1391.e6. PubMed ID: 28734833 [TBL] [Abstract][Full Text] [Related]
7. Comparison of liver oncogenic potential among human RAS isoforms. Chung SI; Moon H; Ju HL; Kim DY; Cho KJ; Ribback S; Dombrowski F; Calvisi DF; Ro SW Oncotarget; 2016 Feb; 7(6):7354-66. PubMed ID: 26799184 [TBL] [Abstract][Full Text] [Related]
8. AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways. Ho C; Wang C; Mattu S; Destefanis G; Ladu S; Delogu S; Armbruster J; Fan L; Lee SA; Jiang L; Dombrowski F; Evert M; Chen X; Calvisi DF Hepatology; 2012 Mar; 55(3):833-45. PubMed ID: 21993994 [TBL] [Abstract][Full Text] [Related]
10. Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer. Tao J; Ji J; Li X; Ding N; Wu H; Liu Y; Wang XW; Calvisi DF; Song G; Chen X Oncotarget; 2015 Mar; 6(9):6977-88. PubMed ID: 25762642 [TBL] [Abstract][Full Text] [Related]
11. SCD1 Expression is dispensable for hepatocarcinogenesis induced by AKT and Ras oncogenes in mice. Li L; Wang C; Calvisi DF; Evert M; Pilo MG; Jiang L; Yuneva M; Chen X PLoS One; 2013; 8(9):e75104. PubMed ID: 24069385 [TBL] [Abstract][Full Text] [Related]
12. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice. Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677 [TBL] [Abstract][Full Text] [Related]
13. Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice. Hu J; Che L; Li L; Pilo MG; Cigliano A; Ribback S; Li X; Latte G; Mela M; Evert M; Dombrowski F; Zheng G; Chen X; Calvisi DF Sci Rep; 2016 Feb; 6():20484. PubMed ID: 26857837 [TBL] [Abstract][Full Text] [Related]
14. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. Ladu S; Calvisi DF; Conner EA; Farina M; Factor VM; Thorgeirsson SS Gastroenterology; 2008 Oct; 135(4):1322-32. PubMed ID: 18722373 [TBL] [Abstract][Full Text] [Related]
15. Metformin delays AKT/c-Met-driven hepatocarcinogenesis by regulating signaling pathways for de novo lipogenesis and ATP generation. Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Zheng G; Qiu Z Toxicol Appl Pharmacol; 2019 Feb; 365():51-60. PubMed ID: 30625338 [TBL] [Abstract][Full Text] [Related]
16. CSIG promotes hepatocellular carcinoma proliferation by activating c-MYC expression. Cheng Q; Yuan F; Lu F; Zhang B; Chen T; Chen X; Cheng Y; Li N; Ma L; Tong T Oncotarget; 2015 Mar; 6(7):4733-44. PubMed ID: 25749381 [TBL] [Abstract][Full Text] [Related]
17. Distinct functions of transforming growth factor-β signaling in c-MYC driven hepatocellular carcinoma initiation and progression. Wang H; Wang P; Xu M; Song X; Wu H; Evert M; Calvisi DF; Zeng Y; Chen X Cell Death Dis; 2021 Feb; 12(2):200. PubMed ID: 33608500 [TBL] [Abstract][Full Text] [Related]
18. TSA attenuates the progression of c-Myc-driven hepatocarcinogenesis by pAKT-ADH4 pathway. Liu Y; Yu J; An X; Rao H; Qiu Z; Ke J; Wu L; Zhu Z; Deng H; Wu F; Zhang Z; Li S BMC Cancer; 2024 Aug; 24(1):1049. PubMed ID: 39187747 [TBL] [Abstract][Full Text] [Related]
19. CUDR promotes liver cancer stem cell growth through upregulating TERT and C-Myc. Pu H; Zheng Q; Li H; Wu M; An J; Gui X; Li T; Lu D Oncotarget; 2015 Dec; 6(38):40775-98. PubMed ID: 26513297 [TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling of MYC-driven tumor signatures in porcine liver stem cells by transcriptome sequencing. Aravalli RN; Talbot NC; Steer CJ World J Gastroenterol; 2015 Feb; 21(7):2011-29. PubMed ID: 25717234 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]